Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H21NO3 |
| Molecular Weight | 371.4284 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C\C=C(\C#CC1=CC=C(C=C1)C2=COC=C2)C3=CC=CC=C3)CC(O)=O
InChI
InChIKey=KIGCTKNPXSPYMQ-XKZIYDEJSA-N
InChI=1S/C24H21NO3/c1-25(17-24(26)27)15-13-22(20-5-3-2-4-6-20)12-9-19-7-10-21(11-8-19)23-14-16-28-18-23/h2-8,10-11,13-14,16,18H,15,17H2,1H3,(H,26,27)/b22-13-
| Molecular Formula | C24H21NO3 |
| Molecular Weight | 371.4284 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:59:46 GMT 2023
by
admin
on
Sat Dec 16 02:59:46 GMT 2023
|
| Record UNII |
26M82RK6TE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9929349
Created by
admin on Sat Dec 16 02:59:46 GMT 2023 , Edited by admin on Sat Dec 16 02:59:46 GMT 2023
|
PRIMARY | |||
|
26M82RK6TE
Created by
admin on Sat Dec 16 02:59:46 GMT 2023 , Edited by admin on Sat Dec 16 02:59:46 GMT 2023
|
PRIMARY | |||
|
337510-16-4
Created by
admin on Sat Dec 16 02:59:46 GMT 2023 , Edited by admin on Sat Dec 16 02:59:46 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
R213129 dose levels were selected based on exposure levels that blocked the GlyT1 sites >50% in preclinical experiments. Forty-three of the 45 included subjects completed the study. Scopolamine significantly affected almost every central nervous system parameter measured in this study. R213129 alone compared with placebo did not elicit pharmacodynamic changes. R213129 had some small effects on scopolamine-induced central nervous system impairments. Scopolamine-induced finger tapping impairment was further enhanced by 3 mg R213129 with 2.0 taps/10 seconds (95% CI -4.0, -0.1), electroencephalography alpha power was increased by 10 mg R213129 with respectively 12.9% (0.7, 26.6%), scopolamine-induced impairment of the Stroop test was partly reversed by 10 mg R213129 with 59 milliseconds (-110, -7).
|
